About Impel Pharmaceuticals
Impel Pharmaceuticals is a company based in Seattle (United States) founded in 2008 was acquired by Jn Bidco in January 2024.. Impel Pharmaceuticals has raised $67.5 million across 6 funding rounds from investors including KKR, HHS and Norwest Venture Partners. Impel Pharmaceuticals offers products and services including Trudhesa and Precision Olfactory Delivery Technology. Impel Pharmaceuticals operates in a competitive market with competitors including Blue Rock Therapeutics, CellCarta, Ascend, RiboPro and Invivyd, among others.
- Headquarter Seattle, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Impel Pharmaceuticals Inc
-
Annual Revenue
$12.65 M1794as on Dec 31, 2022
-
Net Profit
$-106.31 M-39as on Dec 31, 2022
-
EBITDA
$-83.18 M-16as on Dec 31, 2022
-
Total Equity Funding
$67.5 M (USD)
in 6 rounds
-
Latest Funding Round
$67.5 M (USD), Series D
Dec 06, 2018
-
Investors
KKR
& 6 more
-
Employee Count
Employee Count
-
Acquired by
Jn Bidco
(Jan 03, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Impel Pharmaceuticals
Impel Pharmaceuticals offers a comprehensive portfolio of products and services, including Trudhesa and Precision Olfactory Delivery Technology. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treats acute migraine with or without aura in adults.
Enables targeted upper nasal drug absorption for better efficacy.
Unlock access to complete
Unlock access to complete
Funding Insights of Impel Pharmaceuticals
Impel Pharmaceuticals has successfully raised a total of $67.5M across 6 strategic funding rounds. The most recent funding activity was a Series D round of $67.5 million completed in December 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Series D — $67.5M
-
First Round
First Round
(10 Jun 2009)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2018 | Amount | Series D - Impel Pharmaceuticals | Valuation | KKR , Norwest Venture Partners | |
| Nov, 2012 | Amount | Grant - Impel Pharmaceuticals | Valuation |
investors |
|
| Feb, 2012 | Amount | Grant - Impel Pharmaceuticals | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Impel Pharmaceuticals
Impel Pharmaceuticals has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include KKR, HHS and Norwest Venture Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are invested in by this private equity firm.
|
Founded Year | Domain | Location | |
|
Venture capital and growth equity firm providing investments and resources to entrepreneurs in various sectors.
|
Founded Year | Domain | Location | |
|
Venture capital and private equity firm
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Impel Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Impel Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Impel Pharmaceuticals Comparisons
Competitors of Impel Pharmaceuticals
Impel Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Blue Rock Therapeutics, CellCarta, Ascend, RiboPro and Invivyd, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Stem cell therapies are developed for cardiovascular and neurological diseases.
|
|
| domain | founded_year | HQ Location |
Histopathology and genomics services are offered by the CRO.
|
|
| domain | founded_year | HQ Location |
Online insurance payments and premium financing are enabled for businesses.
|
|
| domain | founded_year | HQ Location |
Online supplier and developer of RNA based products
|
|
| domain | founded_year | HQ Location |
Stem cell drug research and clinical trial services are provided.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Impel Pharmaceuticals
Frequently Asked Questions about Impel Pharmaceuticals
When was Impel Pharmaceuticals founded?
Impel Pharmaceuticals was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Where is Impel Pharmaceuticals located?
Impel Pharmaceuticals is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Who is the current CEO of Impel Pharmaceuticals?
Leonard S Paolillo is the current CEO of Impel Pharmaceuticals.
Is Impel Pharmaceuticals a funded company?
Impel Pharmaceuticals is a funded company, having raised a total of $67.5M across 6 funding rounds to date. The company's 1st funding round was a Grant of $149.51K, raised on Jun 10, 2009.
What is the annual revenue of Impel Pharmaceuticals?
Annual revenue of Impel Pharmaceuticals is $12.65M as on Dec 31, 2022.
What does Impel Pharmaceuticals do?
Impel Pharmaceuticals was established in 2008 and is based in Seattle, United States. Operations are centered in the pharmaceutical sector, with emphasis placed on the development and commercialization of innovative therapies. Services are provided for advancing medical treatments from concept to market. The company is led by CEO Leonard S. Paolillo, supporting therapeutic solutions across various health applications.
Who are the top competitors of Impel Pharmaceuticals?
Impel Pharmaceuticals's top competitors include Blue Rock Therapeutics, Ascend and CellCarta.
What products or services does Impel Pharmaceuticals offer?
Impel Pharmaceuticals offers Trudhesa and Precision Olfactory Delivery Technology.
Who are Impel Pharmaceuticals's investors?
Impel Pharmaceuticals has 7 investors. Key investors include KKR, HHS, Norwest Venture Partners, Vivo Capital, and 5AM Ventures.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.